# RWE brief: tzield × Nausea

Data through 2025Q4.

## Filters
Applied: none.
Rows omitted: none.
Counts below are over the rows that survived these filters. n and EB05 are per reported drug string and are never summed or averaged across strings.

## Profile
153 pairs · 2 drugs (tzield, teplizumab). Novel 119 / known 34 / ? 0.
Trend: 8 Accelerating, 13 Rising, 116 New, 15 Stable, 1 Declining
Top EWMA EB05: Mononucleosis syndrome (309.4)
Top n: Nausea (319)
Novel+rising: 9

## Class
Other antidiabetics (A10XX01). 1 substance in Other antidiabetics: too few for a class-wide comparison (needs 3); no drug-specific claim made

## Series
11 quarters 2023Q2–2025Q4, sum n=319. Last 4: 2025Q1 n=36 eb05=5.01 ewma=7.01; 2025Q2 n=40 eb05=5.71 ewma=7.81; 2025Q3 n=47 eb05=5.38 ewma=7.73; 2025Q4 n=43 eb05=4.82 ewma=7.14.

## Pair
Isolated FAERS pair: tzield × Nausea (exact/prefix/substring/same-substance isolation; fuzzy near-matches omitted). Across flagged quarters this pair has n = 319 observed reports, peak quarterly EB05 = 5.71 and peak EWMA EB05 = 7.81 (EB05 is the 5th percentile of the dual-Gamma GPS/EBGM posterior; EWMA is the smoothed series Trend uses). Trend is Rising from last-4 vs prior-4 mean EWMA EB05. Novelty is known (the event term was matched in the cached FDA label text). This is a statistical hypothesis from spontaneous reports, not evidence that the drug causes the event.

---
Built 2026-10-17T03:17:05Z by scripts/build_bot_home.sh from /signals?drug=tzield&event=Nausea&format=brief